How big is Ocugen, Inc.?

As of Jun 18, Ocugen, Inc. has a market capitalization of 318.45 million, with net sales of 4.52 million and a net profit of -57.48 million over the latest four quarters. The company reported shareholder's funds of 29.63 million and total assets of 83.34 million as of Dec 24.

Market Cap: As of Jun 18, Ocugen, Inc. has a market capitalization of 318.45 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Ocugen, Inc. reported net sales of 4.52 million and a net profit of -57.48 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 29.63 million and total assets of 83.34 million.

What does Ocugen, Inc. do?

Ocugen, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for eye diseases. As of March 2025, it has a market cap of $318.45 million, with recent net sales of $1 million and a net loss of $15 million.

Overview: <BR>Ocugen, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for eye diseases within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -15 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 318.45 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.59 <BR>Return on Equity: -361.19% <BR>Price to Book: 20.01<BR><BR>Contact Details: <BR>Address: 5 Great Valley Pkwy Ste 160, MALVERN PA: 19355-1445 <BR>Tel: 1 484 3284698 <BR>Fax: 1 302 6555049 <BR>Website: http://www.histogenics.com/

Should I buy, sell or hold Ocugen, Inc.?

Who are in the management team of Ocugen, Inc.?

As of March 2022, the management team of Ocugen, Inc. is led by Dr. Shankar Musunuri as Chairman and CEO, alongside independent directors Ms. Kirsten Castillo, Dr. Prabhavathi Fernandes, Mr. Uday Kompella, Dr. Ramesh Kumar, and Mr. Manish Potti.

As of March 2022, the management team of Ocugen, Inc. includes Dr. Shankar Musunuri, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, the board features several independent directors: Ms. Kirsten Castillo, Dr. Prabhavathi Fernandes, Mr. Uday Kompella, Dr. Ramesh Kumar, and Mr. Manish Potti.

Is Ocugen, Inc. overvalued or undervalued?

As of February 9, 2024, Ocugen, Inc. is rated as risky due to significant negative financial ratios indicating overvaluation, despite a strong year-to-date stock performance of 73.91%.

As of 9 February 2024, the valuation grade for Ocugen, Inc. has moved from does not qualify to risky, indicating a heightened level of concern regarding its financial health. The company appears to be overvalued given its significant negative ratios, including a Price to Book Value of 19.46, an EV to EBIT of -5.26, and an ROCE of -875.01%. In comparison to peers, Esperion Therapeutics, Inc. has a P/E of -4.9940, while Protalix Biotherapeutics, Inc. is considered attractive with a P/E of 20.0760, highlighting Ocugen's relative underperformance.<BR><BR>Despite recent stock performance showing a 73.91% year-to-date return compared to the S&P 500's 12.22%, the underlying financial metrics suggest that Ocugen's valuation is not supported by its earnings or operational efficiency, reinforcing the conclusion that it is overvalued.

Is Ocugen, Inc. technically bullish or bearish?

As of August 1, 2025, Ocugen, Inc. has a mildly bullish technical trend, supported by strong short-term momentum and positive indicators, despite some mixed signals in longer-term metrics, and has outperformed the S&P 500 with a year-to-date return of 73.91%.

As of 1 August 2025, the technical trend for Ocugen, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a bullish stance for both weekly and monthly periods. Daily moving averages are also bullish. However, the KST shows a mildly bearish signal on both weekly and monthly time frames, and the OBV is mildly bullish weekly but mildly bearish monthly. Dow Theory supports a mildly bullish outlook for both weekly and monthly periods. <BR><BR>In terms of performance, Ocugen has significantly outperformed the S&P 500 with a year-to-date return of 73.91% compared to the S&P 500's 12.22%. Overall, the current technical stance is mildly bullish, driven by strong short-term momentum and positive indicators, despite some mixed signals in longer-term metrics.